Medication Monitor



Generic Name (Trade Name—Company)
Notes
February 12, 2018

Somatropin (rDNA origin)

(Zomacton—Ferring Pharmaceuticals)
Agent approved to treat growth hormone deficiency in adults

Ferring Pharmaceuticals announced FDA approval of somatropin (rDNA origin), a recombinant human growth hormone (GH) indicated for replacement of GH in adults with GH deficiency. It is available in 5-mg and 10-mg options, with the 10-mg dose in a prefilled diluent syringe.

Adult growth hormone deficiency (GHD) occurs in approximately 1 to 2 adults per 100,000 and can be a continuation of childhood onset growth hormone deficiency or have an onset in adulthood resulting primarily from trauma, surgery, or radiation to the head. 

GHD in adults is characterized by metabolic dysfunction, reduced physical strength and activity, altered lipid metabolism. and increases in body fat.

The agent is also indicated for treatment of pediatric patients who have growth failure resulting from inadequate secretion of endogenous growth hormone.

In addition, ZOMA-Jet, a needle-free administration device approved by FDA in 2015, is also available for the 5-mg dose.

 

Somatropin ([rDNA origin] Zomacton—Ferring Pharmaceuticals). This recombinant human growth hormone (GH) is indicated for replacement of GH in adults with GH deficiency. It is available in 5-mg and 10-mg options, with the 10-mg dose in a prefilled diluent syringe.

Adult growth hormone deficiency (GHD) occurs in approximately 1 to 2 adults per 100,000 and can be a continuation of childhood onset growth hormone deficiency or have an onset in adulthood resulting primarily from trauma, surgery, or radiation to the head. 

GHD in adults is characterized by metabolic dysfunction, reduced physical strength and activity, altered lipid metabolism and increases in body fat.

The agent is also indicated for treatment of pediatric patients who have growth failure resulting from inadequate secretion of endogenous growth hormone.

In addition, ZOMA-Jet, a needle-free administration device approved by FDA in 2015, is also available for the 5-mg dose.